retatrutide phase 2 results obesity nejm 2023 VisualAbstract: reduces body weight by 17.5% in patients with Triple hormone receptor agonist retatrutide

ClinicalTrials.gov [Internet] (n.d.) Bethesda (MD): National Library of Medicine

Here is how the math typically works across the research peptide market

Its formulation is intended for subcutaneous injection

The side effect profile mirrors what you'd expect from GLP-1-based drugs: Nausea, particularly when starting or increasing the dose Diarrhoea and, less often, constipation Reduced appetite (which is, of course, partly the point) Tiredness in the first few weeks Occasional vomiting at higher doses In the Phase 2 trials, most side effects were rated mild to moderate and tended to settle as the body adjusted

View Product The Clinical Trial Numbers by Gender The Phase 2 trial (TRIUMPHANT-2) enrolled 338 participants across multiple dosing groups, with the 12mg cohort providing the most telling data on gender-based outcomes

La atencin al cliente suele revelar la madurez de un operador